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Background: Alzheimer’s disease is characterised by a loss of cognitive function and behavioural problems as set
out in the term “Behavioural and Psychological Symptoms of Dementia”. These behavioural symptoms have heavy
consequences for the patients and their families.
A greater understanding of behavioural symptoms risk factors would allow better detection of those patients, a
better understanding of crisis situations and better management of these patients. Some retrospective studies
or simple observations suggested that personality could play a role in the occurrence of behavioural symptoms.
Finally, performance in social cognition like facial recognition and perspective taking could be linked to certain
personality traits and the subsequent risks of behavioural symptoms.
We propose to clarify this through a prospective, multicentre, multidisciplinary study.
Main Objective:
- To assess the effect of personality and life events on the risk of developing behavioural symptoms.
Secondary Objectives:
- To evaluate, at the time of inclusion, the connection between personality and performance in social cognition tests;
- To evaluate the correlation between performance in social cognition at inclusion and the risks of occurrence of
behavioural symptoms;
- To evaluate the correlation between regional cerebral atrophy, using brain Magnetic Resonance Imaging at baseline,
and the risk of behavioural symptoms.
Methods/Design: Study type and Population: Prospective multicentre cohort study with 252 patients with Alzheimer’s
disease at prodromal or mild dementia stage.
The inclusion period will be of 18 months and the patients will be followed during 18 months. The initial
evaluation will include: a clinical and neuropsychological examination, collection of behavioural symptoms
data (Neuropsychiatric-Inventory scale) and their risk factors, a personality study using both a dimensional
(personality traits) and categorical approach, an inventory of life events, social cognition tests and an Magnetic
Resonance Imaging. Patients will be followed every 6 months (clinical examination and collection of behavioural
symptoms data and risk factors) during 18 months.
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Discussion: This study aims at better identifying the patients with Alzheimer’s disease at high risk of developing
behavioural symptoms, to anticipate, detect and quickly treat these disorders and so, prevent serious consequences for
the patient and his caregivers.
Trial registration: ClincalTrials.gov: NCT01297140
Keywords: Alzheimer’s disease, Personality, BehaviourBackground
Alzheimer’s disease (AD) is characterised by both a pro-
gressive cognitive impairment and Behavioural and Psycho-
logical Symptoms of Dementia (BPSD) [1]. BPSD are
frequent in AD. They may occur at any stage of the disease
and progressively worsen as cognitive function declines. Be-
sides the apathy and depression frequently seen in patients
with mild to moderate dementia, some of the other BPSD
such as agitation, irritability, delusions, aberrant motor be-
haviour and hallucinations may be extremely upsetting for
both the patient and his caregivers [2-4]. When they occur
early in the evolution of the disease, their frequency and
the intensity of these BPSD can lead to increased difficulties
in carrying out everyday tasks [5], an increasingly rapid de-
cline in cognitive function [6], a reduction in the quality of
life of both the caregiver and patient [7], an increased likeli-
hood of depression in the caregiver, an increased risk of
hospitalisation, premature institution placement [8] and in-
creased health costs [9].
The difficulty in caring for patients with AD is more
closely linked to the existence and intensity of the BPSD
than the actual cognitive decline. Current treatment for
these BPSD is often difficult but is generally approached
by medications and/or psycho-social support therapies
that still need to be validated.
The prevalence of BPSD has been shown to be in-
creased by a certain number of factors: they may exist at
any stage of the disease but become progressively worse
as cognitive abilities decline. Evolution of the disease
and the level of cognitive impairment have been identi-
fied by several authors [4]. A better understanding of the
risk factors for the onset of BPSD would allow us to bet-
ter target those patients at risk, thus favouring earlier
treatment and so limiting their consequences on pa-
tients, caregivers and the community. The BPSD are the
combined result of neurodegenerative lesions [10], som-
atic comorbidities, iatrogenic effects and also psycho-
logical vulnerability. Clinical experience suggests that
premorbid personality could play a role in the onset of
BPSD with a possible link between personality traits and
specific BPSD.
Nevertheless, very few studies have evaluated the rela-
tionship between premorbid personality, life events and
BPSD. Even childhood trauma could have consequences
for the psychosocial adaptation of the elderly [11] and sofavour the onset of BPSD [12]. A correlation between a
previous history of neuroticism and depression [13,14]
or delusions [15] has been observed in patients with AD.
If a high level of social interaction appears linked to an
increased risk of agitation, the degree of extraversion
does not influence the onset of BPSD [16].
In a previous study, we assessed the influence of pre-
vious psychiatric history, premorbid personality and
family context on the emergence and typology of BPSD
in 99 patients in crisis situations [17]. In this retrospect-
ive study, the prevalence of delusions, anxiety, irritabil-
ity and eating disorders were higher in the patient
group with premorbid personality disorders. Those with
a history of paranoiac, schizoid or schizotypal problems
were more irritable and presented more delusional ten-
dencies. Depression was present in one out of three pa-
tients with obsessive-compulsive, avoidant or dependent
personality disorders. Finally, eating disorders were more
frequent in patients with antisocial, histrionic or narcissis-
tic personalities.
Most of studies assessing the relationship between per-
sonality and BPSD are based on the five factors model that
defines personality using five dimensions: openness, con-
scientiousness, extraversion, agreeability and neuroticism.
A cross sectional study in 208 patients with moderate to
severe Alzheimer’s disease showed an association between
a previous history of neuroticism or agreeableness and
BPSD, especially for previous neuroticism and anxiety and
for previous agreeableness, agitation and irritability [18].
Moreover, a systematic review found a positive relation-
ship between neuroticism and challenging behaviour in
72% of the studies, in particular, mood, aggression and
overall challenging behaviour [19]. However, these retro-
spective studies lacked representative samples and were
impacted by confounding factors and flaws in statistical
analyses. Finally, a recent study including 52 MCI sub-
jects found a relationship between premorbid neuroti-
cism and openness and affective behavioural symptoms
and apathy [20].
Overall, the methodology used in the previous studies
makes interpreting results difficult, particularly as most
studies are retrospective and include only a small num-
ber of patients, often with late stage AD. Such parame-
ters can lead to bias in a patient’s self-evaluation since
cognitive decline invariably leads to modification in the
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of bias comes from collecting data retrospectively from
relatives. This implies subjective judgements, in an
effort to preserve the image of the loved one, it is easy
for family to minimise their BPSD or on the contrary to
overestimate these behavioural problems and their
effects on the family.
Social cognition is a cognitive domain involved in the
detection and the recognition of social and emotional
messages, as well as integration in a personal emo-
tional context and a social complex context. It con-
cerns one of the major aspects of our cognitive
functioning allowing us to interact with our environ-
ment. A key component of social cognition is the
ability to recognize facial emotion expressions, to iden-
tify and to judge mental state and the intentions of the
others. It has been shown that impairment in the
ability to recognise facial expressions is correlated to
social behaviour in various psychiatric and neuro-
logical pathologies [21,22]. Recent work has already
shown that patients with AD also had impaired ability
to recognise facial expressions [23]. Thus, impairment
of social cognition ability in AD could influence the
onset and the course of BPSD. Moreover, performance
in social cognition tests like facial recognition and per-
spective taking could be linked to certain personality
traits and the subsequent risk of BPSD.
Furthermore, imaging markers could help to under-
stand the link between brain structures changes and the
presence of BPSD. The neuropsychiatric symptoms ob-
served in AD patients could be mainly due to frontal
structural abnormalities [24]. More specific regional as-
sociations with a range of behavioural symptoms have
been identified: apathy was associated with frontal struc-
tures [25]; delusions were correlated with frontal, par-
ietal, and temporal structures [26]; depressive symptoms
with thalamus, lentiform nucleus, and medial temporal
cortex [27]; agitation was associated with temporal and
frontal structures [28] and amygdale atrophy was re-
lated to aberrant motor behaviour, with potential rela-
tionships to anxiety and irritability [29]. These same
regions participate in the recognition of social messages,
particularly those of facial expression, perspective tak-
ing and empathy [30]. Consequently, measurement of
MRI markers may allow us to better understand the link
between personality, social cognition and BDSP and the
implication of the anatomic structures in these different
domains.
We propose to assess personality in patients with pro-
dromal or mild AD, and then to collect BPSD data pro-
spectively with the objective to evaluate the causality
link between personality and BPSD occurrence. Social
cognition performance and cortical atrophy will also be
measured at baseline.Study aim and research question
A. Main objective
– To measure the effect of premorbid personality and
life events on the likelihood of a patient with
probable Alzheimer’s disease on the risk of
developing BDSP.
B. Secondary objectives
– To evaluate the relationship between premorbid
personality and performance in social cognition
testing,
– To evaluate the relationship between performance in
social cognition testing at study inclusion and the
risk of developing BPSD,
– To evaluate the relationship between the
distribution of regional cerebral atrophy using 3D
brain MRI at study inclusion, social cognition
performance and the risk of developing BPSD.
Methods/design
Study design
This study is a multicentre prospective cohort study of
patients with Alzheimer’s disease. Patients will be
followed up over a period of 18 months. At baseline
visit, the patients will undergo both a clinical and
neuropsychological examination, a study of their per-
sonality and important life events, social cognition and
blood tests (to screen for exclusion criteria) and a brain
MRI. If inclusion is confirmed, the patients will then be
followed at 6-month intervals for at least 18 months.
Setting
The study is being conducted in memory centers of the
University hospitals of Lyon, Saint Etienne, Grenoble,
Dijon, Bordeaux, Strasbourg, memory centers of Saint
Chamond, Annecy and Colmar and Lyon psychiatric
hospital.
Population
Inclusion criteria are: diagnostic criteria for AD at mild
dementia stage, (NINCDS ADRDA and CDR 1) [31] or
prodromal AD (CDR of 0.5) [32], age over 50 years,
ability to complete the clinical and neuropsychological
evaluations, and presence of a caregiver in sufficient
contact with the subject to be able to note the onset of
changes in behaviour.
Exclusion criteria include: patients with SCPD except
from depression, anxiety, apathy, eating or sleep dis-
orders at mild stage, patients with a progressive and/or
poorly managed psychiatric pathology (patients with
stabilised depression could be included in the study),
patients taking any neuroleptic psychotropic medication,
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exception of any antidepressant, hypnotic, anxiolytic,
acetylcholinesterase inhibitors or Memantine which has
been prescribed and stabilised for more than 3 months,
and patients with serious, progressive or unstable path-
ologies which could interfere with the variables under
consideration.
Informed consent and ethical consideration
Informed written consent is obtained from subject and
caregiver before baseline assessment takes place. The
study protocol has been reviewed and approved by an
ethics committee (Comité de Protection des Personnes
Lyon Sud Est III). All procedures are in accordance with
the declaration of Helsinki.
Measures
Personality
Personality will be assessed with both categorical and
dimensional approaches. The categorical approach looks
for personality disorders which are indicative of an
underlying psychiatric pathology. The patient will take
part in a semi-structured consultation based on the
Structural Clinical Interview for DSM-IV Axis II Dis-
orders (SCID II) [33,34]. The diagnosis will also deter-
mine depressive and passive-aggressive personalities
included in annexe B of DSM IV. The personality disorder
will then be confirmed by collegial decision.
The dimensional approach describes the character
traits of each subject. This is done using the NEO PI-R,
a widely used questionnaire to assess personality using
the « Five-Factor Model » each with 6 facets to each of
five major personality types. The « big five » model [35]
defines 5 basic personality traits: extraversion, openness,
agreeableness, neuroticism and conscientiousness.
Life events
Major events that may have had an impact on the patient’s
future health will be collected using the Clément
questionnaire [36] and the French life events scale
designed by Ferreri and Vacher [37], which concentrates
on traumatic events in the areas of family life, career,
social life, intimate relationships and health. Since the use
of these questionnaires has not been validated yet, they
will be offered as an additional tool during clinical
examination.
Assessment of mood
Any current symptomatology indicative of depression
will be evaluated using the Geriatric Depression Scale
(GDS) which has been validated for use in the elderly
[38]. This 30-item scale has proved its usefulness in
detecting depressive symptoms in patients presentingwith mild dementia. Previous instances of depression
will be measured using the MINI [39].
Clinical and neuropsychological assessments
An interview, a neurological and general examination
will be undertaken by the neurologist, geriatrician or
psychiatrist in charge of the patient. Factors favouring
BPSD such as family situation, living conditions and
intercurrent pathologies will be investigated as will
caregiver health using the mini-Zarit test [40].
A standardised battery of neuropsychological tests
will be used in the study centres. The Mini Mental State
Examination (MMSE) will be used to evaluate global
cognitive function [41], the 16-item Free and Cued
Recall Test (FCRT) to evaluate verbal episodic memory
[42], the Delayed Matching-to-Sample (DMS48) test to
evaluate visual recognition memory [43], the Trail Making
Test (TMT) [44] and the Stroop test [45], to evaluate
executive function, Isaac’s set test to evaluate verbal
fluency, the Frontal Assessment Battery (FAB) and the
frontotemporal behaviour scale to evaluate dysexecutive
behavioural syndrome [46], an 80 item object naming
test to evaluate language, a Rey Figure reproduction to
evaluate visual construction; meaningless gestures
comprehension test assessment will assess praxis.
Finally, abilities to perform instrumental activities will
be evaluated with the Instrumental Activities of Daily
Living (IADL) scale [47,48].
Social cognition
Subjects were engaged in five tasks, including two
successive facial feature recognition tasks:
– A test for recognition of facial emotional expression:
static colour photographic images of 4 facial
emotional expressions (happiness, fear, anger and
disgust) were morphed with neutral faces to create
an expression continuum. After each face
presentation, participants were asked to decide which
of five labels (happy, fearful, angry, disgusted, or
neutral) best described the presented facial expression
using a forced-choice paradigm. Photographs of two
female and two male faces depicting basic
emotions (happiness, fear, anger and disgust)
morphed with a neutral face in 10% steps were
randomly presented [21].
– A test for recognition of the facial gender: likewise,
photographs of the faces of the 2 sexes (males and
women) were morphed with a face depicting “no
sex” to create a continuum. The “no sex” was
obtained by averaging 20 male and 20 female faces.
Eight females and eight males morphed with an
average face in 10% steps were randomly presented.
Each face had a neutral expression. After each face
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the face using a forced-choice paradigm (man or
woman) [21].
– A test to detect eye gaze: this uses photographs of
the faces of 8 men and 8 women looking 5, 10, 15,
20, 25 or 30° to the right or left. This gives a total
of 96 images which are presented in random order.
The subject then has to decide whether the person
is looking to the right or left [21].
– two tests to assess the subject’s perspective,
including: a verbal test to assess the subject’s
ability to describe his own reactions (1st person)
and those of his spouse or partner (3rd person)
in a variety of social situations presented orally
which could be described either as socially neutral
or socially emotive [49]; a visual test to assess the
subject’s ability to discern the intentions of others
using a short scenario presented as three cartoon
drawings. From the subject’s interpretation of the
situation and the expected behaviour of one of the
characters, he must choose the logical conclusion
to the story from among 3 images. A control task
uses a scenario that has no character, designed to
investigate the subject’s ability to explore and
analyse a situation and find a suitable response
to it [50].
Outcome measures: BPSD assessment
Behavioural problems will be assessed during the initial
and each subsequent consultation with the patient then
by questioning his caregiver. The shortened form of the
Neuropsychiatric Inventory (NPI-Q) and the Apathy
Inventory will be used.
The NPI-Q is a questionnaire designed to collect infor-
mations on neuropsychiatric problems to patients with
cerebral disorders. It is an assessment questionnaire ad-
ministered to the caregiver. It is only designed to evaluate
the severity of symptoms and their effect on the caregiver
and not their frequency. Twelve types of neuropsychiatric
symptoms are covered by the questionnaire: delusions,
hallucination, agitation, depression, anxiety, euphoria,
apathy, impulsive behaviour, mood swings, aberrant motor
behaviour and problems with eating and sleeping.
Symptoms of apathy will also be assessed using the
Apathy Inventory [51]. This provides descriptive assess-
ment of the form this apathy takes, from emotional
indifference to lack of initiative and total disinterest in
life. The information can be obtained from both the
patient and his principal caregiver.
MRI
A morphologic MRI will be performed as part of the bat-
tery of exploratory tests usually carried out. Acquisition
will be performed on a 1.5 Tesla systems. The examinationwill include a 3D T1-weighted sequence an axial T2 se-
quence an axial T2* sequence and an axial FLAIR se-
quence. Voxel Based Morphometry (VBM) procedures
will be used to analyze brain volumes and to evaluate the
correlation between the score obtained by subjects and
the grey matter density on their anatomical MRI scans.
The segmentation of 3D T1-weighted images will be per-
formed using SPM2 software and the optimized VBM
method described by Senjem et al. [52].
The different measure variables used in PACO study
are summarized in Table 1.
Data collection procedures:
1- Initial assessment
Patients and their caregivers recruited in memory
centres will give informed consent. A range of
baseline measurements will include clinical interview
and examination, assessment of BPSD (NPI and
Apathy Inventory). A psychiatric consultation will
evaluate previous psychiatric history (MINI),
attribution of personality type and/or impairment
(NEO PI-R and SCID II) and history of life events.
Patients will then undergo neuropsychological
assessment and social cognition tests. Biological tests
(blood sample) and medical imaging (cerebral IRM)
will be done according to usual medical practice.
2- Follow-up
Patients will be followed-up by clinicians at 6 months,
12 months and 18 months. This consultation, besides
the standard interview and clinical examination, will
include collection of information related to BPSD
(NPI and Apathy Inventory) and any factors which
may influence behaviour, in particular environment
data, caregiver’s burden and concomitant diseases.
The different stages of data collection procedure are
summarized in Figure 1.
Sample size
This has been calculated as a function of our main ob-
jective. From the hypothesis that BPSD occurs in 40% of
patients [2] with a relative risk (RR) of 1.5 in relation to
premorbid personality, the estimated number of sub-
jects is 210 patients for an alpha risk of 5% and a power
of 90%. With an expected drop-out rate of 20% over
3 years i.e. 42 patients, the total population required is
252 patients.
Data analysis
To assess each study objectives, univariate and then
multivariate analyses will be done to take into account
potential confusion factors:
To evaluate the link between personality (traits and
disorders) and the onset of BPSD, exploratory analyses
Table 1 Measurements instruments used in the PACO study
Variable Instrument/source Type of variable
Demographic variables Single items Control variables
Diagnosis variables NINCDS ADRDA Control variables
CDR
Psychotropic medications Single items Control variables
Personality type NEO PI R Influencing factor
Personality trouble SCID 2 Influencing factor
Life events Clément questionnaire and French Life events Inventory Influencing factor
Depression GDS (current depression) Influencing factor
MINI (history of depression)
Neuropsychological tests Assessment of memory, attention, executive functions,
language, praxis and global cognitive functions.
Influencing factor
Social cognition tests facial emotional expression; Influencing factor
recognition of the facial gender; Secondary outcome variable
recognition of the facial gender;
Theory of Mind tests;
Neuroimaging measures MRI Atrophy measurement Influencing factor
Secondary outcome variable
Neuropsychiatric symptoms Neuropsychiatric Inventory (NPI-Q) Primary outcome measure
Neuropsychiatric symptoms Apathy Inventory Primary outcome measure
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order and type of BPSD will be used.
Logistic regression models will be used for binary vari-
ables obtained from the NPI-Q and the Apathy Inventory,
and linear regression models for continuous explanatory
variables: intensity of the behavioural problems and total
NPI-Q score.Visit  1 Visit 2 Follow-
up visit 1
2 months 6 months
Visit 3
1 month
Figure 1 Typical schedule for a patient enrolled in the PACO protocol: s
BDSP and their risk factors. Visit 2: psychiatric assessment. Visit 3: neuropsycho
sampling. Follow-up visits: clinical visit including assessment of BDSP and theiANOVA with repeated measures and survival models
will be used to study the occurrence of these BPSD over
time as seen during the various visits.
Exploratory analyses will be done to define a patient’s
typology. Then, correlation between personality type and
performance on social cognition tests will be assessed
using linear regression models.Follow-
up visit 2
Follow-
up visit 3
6 months 6 months
ummary of different stages. Visit 1: clinical visit including assessment of
logical assessment and social cognition tests; medical imaging and blood
r risk factors.
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nition tests and the risk for the onset of BPSD will be
assessed with logistic regression models and survival
models.
Finally, correlation between the type of BPSD and the
difference in distribution of regional cerebral atrophy
observed with MRI will be done using specific statistical
parametric mapping (SPM) software.
Discussion
The PACO study aims to better understand the factors
underlying neuropsychiatric symptoms in patient with
baseline prodromal or mild AD. This prospective multi-
disciplinary project brings together specialists in old age
psychiatry, geriatric and neurology. Its main objective is
to evaluate the effect of premorbid personality on the
phenomenology and the frequency of BPSD. Premorbid
personality will be assessed with the Five Factors Model,
which is considered as the most widely used dimensional
personality approach [53].
Several studies suggest that personality may influence
the behavioral course of AD [19]. It has been yielded
that persons with high neuroticism experience have
more behavioral disturbances when measured with NPI
[18]. The association between personality and specific
neuropsychiatric symptoms is so far not fully established
and should be better specified. For instance, high levels
of neuroticism have been sometimes linked to depres-
sion [54] or not [18]. Most studies in this field are retro-
spective and include few patients, often in advanced
stages of the disease. It can induce a substantial risk of
recall bias, especially when personality is assessed by in-
formants. The longitudinal design of PACO project, in-
cluding more than 250 AD patients at prodromal or
mild stage, can control some of these biases. Self-report
of personality has been preferred to observer rating. In
healthy people, this methodology is considered to be
more accurate and trustworthy because observers do not
have access to a person’s internal motives [55]. In the
context of cognitive decline, self-assessment of personal-
ity could be criticized. However, Archer et al. showed
that the NEO-FFI, a personality questionnaire based on
the Big Five Inventory, can be used reliably to measure
premorbid personality in AD patients [56]. Moreover, it
has been shown that when asked to evaluate their
current personality, persons with mild AD tended to de-
scribe their former personality [57], maybe due to an in-
ability to update their self-image [58].
In PACO study, we are expecting to find correlations
between personality dimensions and the risk of being af-
fected by BPSD. We hypothesize that high level of neur-
oticism and low level of conscientiousness will be more
specifically associated with BPSD, in particular affective
domains such as depression, anxiety and apathy. Ascognitive decline could be positively or negatively influ-
enced by personality, this potential association will be
studied [59,60]. Moreover, as personality development is
considered to be influenced by environmental factors,
childhood and adult life events will be collected to assess
their possible influence on the course of AD. This would
allow us, for example, to highlight the possible effects of
previous exposure to a trauma or childhood deficiencies.
Subjects included in PACO study will perform a compre-
hensive social cognition battery including facial emotion
recognition tasks. Several publications have highlighted
that AD patients experience an increasing deficit in facial
emotional expression recognition as the disease progresses
[23], but little is known concerning the very early stage of
AD [61]. Consequences of impaired facial emotion recog-
nition on behavioral troubles in AD are questioned and
should be clarified [62]. Thus, a secondary objective of the
PACO study is to compare social cognition ability between
MCI and mild AD, and to identify potential relationships
between social cognition abilities and BPSD occurrence
during the patient’s follow-up.
PACO project includes MRI 3D sequence at baseline.
Different studies have linked impaired emotion recogni-
tion in psychiatric or neurologic disease to disturbances or
damages of the fronto-temporal brain network [63-65].
Social cognition parameters could be correlated to initial
regional cerebral volume and/or the atrophy observed one
year later, which could itself be correlated to a higher risk
of developing BPSD. For instance, some orbito-frontal at-
rophy may predict the occurrence of BPSD. Recent evi-
dence suggests that personality traits may be related to
neuroanatomical structures. Jackson et al. [66] found
that higher neuroticism was associated with specific
brain regions atrophy, whereas higher conscientiousness
was related to larger regional volumes in healthy aging.
It could be hypothesised that an interaction between
personality dimension, regional brain atrophy, and
BPSD may exist in AD.
The PACO study may have several limitations. Firstly,
personality should ideally have been assessed before AD
onset. However, it would have been necessary to include
a very large number of patients with a long follow-up.
We have chosen to include patients at early stage of AD:
at this stage we can suppose that the personality assess-
ment reflects premorbid personality. Secondly, a longer
follow-up would allow us to detect a larger number of
BDSP. The absence of long-term follow-up could under-
estimate the relationship between personality and BDSP.
Indeed, a certain number of SCPD increase with the
evolution of the disease, but we hypothesized that some
of them occur early in patients with specific personality
traits. Thirdly, at baseline only patients with no or mild
behavioural disturbances are selected. This inclusion meth-
odology excludes subjects with personality dimensions
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diagnosis was based on clinical and MRI criteria. Dubois
et al. criteria refer to both imaging and to CSF markers
[67]. This would allow better patient selection. However,
in our centres, CSF markers are available for a small per-
centage of the patients, in particular when the diagnosis
remains unclear. On the opposite, patients included in the
PACO study had a typical clinical presentation, and CSF
markers were not available for the majority of them. A
systematic lumbar puncture should have limited the
feasibility of our study.
The present study also has strengths. In most former
studies personality assessment was performed by rela-
tives and only a few included patients at prodromal or
mild stage of AD. Moreover, to our knowledge, PACO is
the first study to evaluate personality and social cogni-
tion performance and their link with subsequent BDSP.
The results of this research may help clinicians to bet-
ter indentify, from a combined assessment of personal-
ity, performance in social cognition tests and the degree
of cerebral atrophy, patients with AD at enhanced risk
of developing BPSD and to improve patient and family
care. Demonstrating a link between premorbid personal-
ity and behavioural problems will also allow us to argue
for a veritable cooperation between neurologists, geria-
tricians and psychiatrists in the patients care throughout
the course of the disease.
This study also aims to better understand the reper-
cussions of early stage AD on social behaviour, identify
the neuroanatomical correlates of BPSD. It should allow
us to set up a regional data base to include clinical,
neuropsychological, psychiatric, neuroradiological and
biological data with longitudinal follow-up of the cohort,
and then further inter-regional and inter-speciality cooper-
ation in studying and dealing with Alzheimer’s disease.
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